1 |
Anastasiadis A, de Reijke TM. Best practice in the treatment of nonmuscle invasive bladder cancer. Ther Adv Urol 2012;4(1): 13-32.
DOI
|
2 |
National Cancer Institute. Cancer stat facts: bladder cancer [cited 2017 Nov 20]. Available from: https://seer.cancer.gov/statfacts/html/urinb.html.
|
3 |
American Cancer Society. Survival rates for bladder cancer [cited 2018 Jan 3]. Available from: https://www.cancer.org/cancer/bladder-cancer/detection-diagnosis-staging/survival-rates.html.
|
4 |
Cheng L, MacLennan GT, Lopez-Beltran A. Histologic grading of urothelial carcinoma: a reappraisal. Hum Pathol 2012;43(12): 2097-2108.
DOI
|
5 |
MacLennan GT, Kirkali Z, Cheng L. Histologic grading of noninvasive papillary urothelial neoplasms. Eur Urol 2007;51(4): 889-897.
DOI
|
6 |
Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005;66(6 Suppl 1):4-34.
DOI
|
7 |
Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Comperat E, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 2013;64(4):639-653.
DOI
|
8 |
Bobinski J, Lipinski M. EORTC risk tables--a new diagnostic tool in urology. Pol Merkur Lekarski 2009;27(162):524-528 (Polish).
|
9 |
Barton MK. High morbidity and mortality found for high-risk, non-muscle-invasive bladder cancer. CA Cancer J Clin 2013; 63(6):371-372.
DOI
|
10 |
Snyder C, Harlan L, Knopf K, Potosky A, Kaplan R. Patterns of care for the treatment of bladder cancer. J Urol 2003;169(5):1697-1701.
DOI
|
11 |
Hollenbeck BK, Dunn RL, Ye Z, Hollingsworth JM, Lee CT, Birkmeyer JD. Racial differences in treatment and outcomes among patients with early stage bladder cancer. Cancer 2010;116(1): 50-56.
DOI
|
12 |
Underwood W 3rd, Dunn RL, Williams C, Lee CT. Gender and geographic influence on the racial disparity in bladder cancer mortality in the US. J Am Coll Surg 2006;202(2):284-290.
DOI
|
13 |
Seo KW, Kim BH, Park CH, Kim CI, Chang HS. The efficacy of the EORTC scoring system and risk tables for the prediction of recurrence and progression of non-muscle-invasive bladder cancer after intravesical bacillus calmette-guerin instillation. Korean J Urol 2010;51(3):165-170.
DOI
|
14 |
National Cancer Institute. Site recode ICD-O-3 (1/27/2003) definition [cited 2018 May 17]. Available from: https://seer.cancer.gov/siterecode/icdo3_d01272003/.
|
15 |
Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Vicente-Rodriguez J. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 2000; 163(1):73-78.
DOI
|
16 |
National Cancer Institute. Number of persons by race and Hispanic ethnicity for SEER participants (2010 census data 1) [cited 2018 May 17]. Available from: https://seer.cancer.gov/registries/data.html.
|
17 |
National Cancer Institute. SEER program coding and staging manual 2016; 2016 [cited 2018 May 17]. Available from: https:// seer.cancer.gov/archive/manuals/2016/SPCSM_2016_maindoc.pdf.
|
18 |
National Cancer Institute. AJCC cancer staging [cited 2018 May 17]. Available from: https://seer.cancer.gov/seerstat/variables/seer/ajcc-stage/.
|